Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP.
Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP.
复制标题
补体 C1qA276 的纯合 A 多态性与接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者的总生存期延长相关
DOI：
10.1186/1756-8722-5-51
复制
发表时间：
2012-08-16
影响因子：
28.5
通讯作者：
Zhu J
中科院分区：
文献类型：
--
作者：
Jin X;Ding H;Ding N;Fu Z;Song Y;Zhu J
利妥昔单抗（R）的确切作用机制尚未完全阐明。除了抗体依赖性细胞毒性（ADCC）外，补体也可能在弥漫性大B细胞淋巴瘤（DLBCL）对利妥昔单抗治疗的临床反应中发挥重要作用。本研究的目的是探讨C1 qA [276]多态性与DLBCL患者对R-CHOP标准一线治疗的临床反应之间的关系。在164例DLBCL患者中进行了C1 qA [276 A/G]基因分型。129例接受R-CHOP作为一线治疗（R ≥ 4个周期）的患者可评估疗效。A等位基因纯合子患者的总有效率高于G等位基因杂合子或纯合子患者（97.3%vs.83.7%，P = 0.068）。A纯合子患者的完全缓解率明显高于AG和GG等位基因携带者（89.2%vs.51.1%，P = 0.0001）。A等位基因纯合子患者的总生存期长于G等位基因携带者（676天vs.497天，P = 0.023）。多因素考克斯回归分析显示，C1 qAA/A等位基因是DLBCL患者接受R-CHOP一线治疗的独立有利预后因素。这些结果表明，C1 qA多态性可能是预测DLBCL患者对R-CHOP一线治疗反应的生物标志物。
The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of this study was to explore the relationship between C1qA[276] polymorphism and the clinical response to standard frontline treatment with R-CHOP in DLBCL patients. Genotyping for C1qA[276A/G] was done in 164 patients with DLBCL. 129 patients treated with R-CHOP as frontline therapy (R ≥ 4 cycles) were assessable for the efficacy. Patients with homozygous A were found to have a higher overall response rate than those with heterozygous or homozygous G alleles (97.3% vs. 83.7%,P = 0.068). The complete response rate in patients with homozygous A was statistically higher than that in AG and GG allele carriers (89.2% vs. 51.1%,P = 0.0001). The overall survival of patients with homozygous A was longer than that of the G allele carriers (676 days vs. 497 days, P = 0.023). Multivariate Cox regression analysis showed that C1qA A/A allele was an independent favorable prognostic factor for DLBCL patients treated with R-CHOP as first-line therapy. These results suggest that C1qA polymorphism may be a biomarker to predict response to R-CHOP as frontline therapy for DLBCL patients.
登录
查看更多内容
影响因子：
10.9
作者：
Elbaz HA;Stueckle TA;Tse W;Rojanasakul Y;Dinu CZ
通讯作者：
Dinu CZ
影响因子：
28.5
作者：
Wang J;Ke XY
通讯作者：
Ke XY
影响因子：
51.1
作者：
Pfreundschuh, Michael;Trumper, Lorenz;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
3.5
作者：
Stuart, GR;Lynch, NJ;Schwaeble, WJ
通讯作者：
Schwaeble, WJ
DOI：
10.1084/jem.188.12.2349
发表时间：
1998-12-21
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Pike SE;Yao L;Jones KD;Cherney B;Appella E;Sakaguchi K;Nakhasi H;Teruya-Feldstein J;Wirth P;Gupta G;Tosato G
通讯作者：
Tosato G